Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY +1.49%77 EV-to-Revenue is 4.31 as of Aug. 04, 2026, which is 49% below its 10-year median of 8.40. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Coloplast AS ranks worse than 65.81% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Coloplast AS's enterprise value is $18,848 Mil.
Coloplast AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $4,370 Mil. Therefore, Coloplast AS's EV-to-Revenue for today is 4.31.
The historical rank and industry rank for Coloplast AS's EV-to-Revenue or its related term are showing as below:
CLPBY'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.87 Med: 8.4 Max: 13.12
Current: 4.31
During the past 13 years, the highest EV-to-Revenue of Coloplast AS was 13.12. The lowest was 3.87. And the median was 8.40.
CLPBY's EV-to-Revenue is ranked worse than 65.81% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.97
vs CLPBY: 4.31
As of today (2026-08-04), Coloplast AS's stock price is $6.80.
Coloplast AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.94. Therefore, Coloplast AS's PS Ratio for today is 3.50.
Coloplast AS's share price for today is $6.80.
Coloplast AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS EV-to-Revenue Related Terms
Coloplast AS EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Coloplast AS's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: EV-to-Revenue Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS EV-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Coloplast AS's EV-to-Revenue falls into.
Coloplast AS's current Enterprise Value is $18,848 Mil.
Coloplast AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,370 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBY) has a EV-to-Revenue of 4.31 as of Aug. 04, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Coloplast AS and its competitors. This is 49% below median its historical median of 8.40. Over the past decade, Coloplast AS's EV-to-Revenue has ranged from 3.87 to 13.12. According to the industry distribution chart, Coloplast AS ranks #537 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is Coloplast AS's EV-to-Revenue too high?
Coloplast AS's current EV-to-Revenue of 4.31 is 49% below median its 10-year median of 8.40. Over the past 10 years, this metric has ranged from a low of 3.87 to a high of 13.12. The Medical Devices & Instruments industry median EV-to-Revenue is 2.97. Coloplast AS's value of 4.31 is 45.1% above this industry median. Based on the distribution chart, Coloplast AS ranks #537 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's EV-to-Revenue compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #537 out of 816 companies for EV-to-Revenue. This places Coloplast AS in the lower half of its industry. The industry median EV-to-Revenue is 2.97. Coloplast AS's value of 4.31 is 45.1% above this benchmark. Historically, Coloplast AS's own EV-to-Revenue has ranged from 3.87 to 13.12 over the past decade. While the company's 10-year median is 8.40 vs. the industry median of 2.97, Coloplast AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Devices & Instruments company?
The median EV-to-Revenue among Medical Devices & Instruments companies is 2.97, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current EV-to-Revenue of 4.31 is 45.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-Revenue is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current EV-to-Revenue is 4.31, which is 49% below median its own 10-year median of 8.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.80 — trading 47.9% below its estimated fair value. The current EV-to-Revenue is 4.31, which is 49% below median its 10-year median of 8.40 and 45.1% above the Medical Devices & Instruments industry median of 2.97. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current EV-to-Revenue is 4.31 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.80 is trading 47.9% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
EV-to-Revenue: 4.31 (49% below median its 10-year median of 8.40)
GF Value™: $13.05 vs. price of $6.80 (47.9% below fair value)
Industry Position: 45.1% above the Medical Devices & Instruments median (#537 of 816)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
